CDDO-TFEA is primarily investigated for its potential therapeutic applications, particularly in the treatment of inflammatory diseases and cancer. Its mechanism of action involves the activation of the Nrf2 pathway, which plays a crucial role in cellular defense against oxidative stress. This makes it a promising candidate for managing conditions like chronic obstructive pulmonary disease (COPD), where oxidative damage is a key factor. Additionally, its anti-inflammatory properties are being explored for use in autoimmune disorders such as rheumatoid arthritis and multiple sclerosis. In cancer research, CDDO-TFEA has shown potential in inhibiting tumor growth and inducing apoptosis in various cancer cell lines, making it a subject of interest for developing novel anticancer therapies. Its ability to modulate key signaling pathways also suggests potential applications in neurodegenerative diseases, where oxidative stress and inflammation are contributing factors. Ongoing studies continue to explore its efficacy and safety in these areas.